Drug & intervention

tremelimumab

RxCUI 2619313

Clinical trials45
Recruiting4
Related conditions20
Synonyms2

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

40 shown
A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous DurvalumabNCT07391670 · 2026-03-31
RECRUITING
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)NCT06564623 · 2025-05-27
RECRUITING
Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLCNCT04585490 · 2021-08-25
RECRUITING
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung CancerNCT04499053 · 2020-12-09
RECRUITING
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRASNCT06008093 · 2024-04-04
ACTIVE_NOT_RECRUITING
Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant TreatmentNCT04625699 · 2022-12-01
WITHDRAWN
......SMARTEST Trial......NCT05380713 · 2022-05-03
COMPLETED
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver TransplantNCT05027425 · 2021-12-07
TERMINATED
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid TumorsNCT03982173 · 2020-09-01
WITHDRAWN
Microbiome Immunotherapy Toxicity and Response EvaluationNCT04107168 · 2020-07-08
UNKNOWN
Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLCNCT03965468 · 2019-11-19
ACTIVE_NOT_RECRUITING
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and TremelimumabNCT03638141 · 2019-10-02
COMPLETED
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung CancerNCT03923270 · 2019-06-06
ACTIVE_NOT_RECRUITING
Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the TreatmentNCT04287894 · 2018-12-28
TERMINATED
A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)NCT03975114 · 2018-12-20
UNKNOWN
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid TumorsNCT03693612 · 2018-11-26
COMPLETED
Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)NCT03319316 · 2018-11-01
WITHDRAWN
Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.NCT03994393 · 2018-10-23
UNKNOWN
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation TherapyNCT03703297 · 2018-09-27
ACTIVE_NOT_RECRUITING
Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid TumorsNCT03509012 · 2018-05-02
COMPLETED
Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint InhibitionNCT03275597 · 2018-02-20
TERMINATED
Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLCNCT03164772 · 2017-12-20
COMPLETED
SGI-110 Plus Durvalumab/Tremelimumab in SCLCNCT03085849 · 2017-12-15
COMPLETED
Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung CancerNCT03237377 · 2017-12-12
TERMINATED
A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic CancerNCT03212469 · 2017-06-20
COMPLETED
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).NCT03164616 · 2017-06-01
ACTIVE_NOT_RECRUITING
Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung OriginNCT03095274 · 2017-04-11
COMPLETED
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLCNCT03057106 · 2017-03-28
ACTIVE_NOT_RECRUITING
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)NCT03043872 · 2017-03-27
ACTIVE_NOT_RECRUITING
Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLCNCT03130764 · 2017-03-01
WITHDRAWN
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersNCT02643303 · 2016-12-28
COMPLETED
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate CancerNCT02788773 · 2016-12-15
COMPLETED
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell TransplantNCT02716805 · 2016-12-13
TERMINATED
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)NCT02821754 · 2016-07-05
COMPLETED
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal CancerNCT02735239 · 2016-06-24
COMPLETED
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic CancersNCT02639026 · 2016-01-26
COMPLETED
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid TumoursNCT02586987 · 2015-12-28
COMPLETED
Brain Irradiation and Tremelimumab in Metastatic Breast CancerNCT02563925 · 2015-09-18
COMPLETED
Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung CancerNCT02179671 · 2014-07-25
COMPLETED
Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC PatientsNCT02040064 · 2014-01-01
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.